Role of Iron in Neurodegenerative Disorders

Although the pathophysiology underlying a number of neurodegenerative diseases is complex and, in many aspects, only partly understood, increased iron levels in pathologically relevant brain areas and iron-mediated oxidative stress seem to play a central role in many of them. Much has been learned from monogenetically caused disturbances of brain iron metabolism including pantothenate kinase-associated neurodegeneration type 2, hereditary ferritinopathies affecting the basal ganglia, and aceruloplasminemia that may well be applied to the most common neurodegenerative disorders associated with brain iron accumulation including Parkinson disease and Alzheimer disease. Iron-mediated oxidative stress in neurodegenerative diseases caused by other genetic pathways like Huntington disease and Friedreich ataxia underscore the complex interaction of this trace metal and genetic variations. Therapeutical strategies derived from application of iron chelators in monogenetically caused disturbances of brain iron metabolism and new iron and oxidative stress diminishing substances in animal models of Parkinson disease are promising and warrant further investigational effort.

[1]  Steven M LeVine,et al.  Iron deposits in multiple sclerosis and Alzheimer's disease brains , 1997, Brain Research.

[2]  Luisa Mola Morales,et al.  Serum ferritin deficiency in Huntington's disease patients , 1991, Neuroscience Letters.

[3]  J. Østergaard,et al.  In vivo Diagnosis of Hollervorden‐Spatz Disease , 1995 .

[4]  M. Youdim,et al.  Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. , 1996, European journal of pharmacology.

[5]  M. Youdim,et al.  Nutritional Iron Deprivation Attenuates Kainate‐Induced Neurotoxicity in Rats: Implications for Involvement of Iron in Neurodegeneration , 2004, Annals of the New York Academy of Sciences.

[6]  Raffaella Mariani,et al.  MR imaging of cerebral cortical involvement in aceruloplasminemia. , 2005, AJNR. American journal of neuroradiology.

[7]  Daniela Berg,et al.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.

[8]  E. Kremmer,et al.  α-Synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies , 2000, Acta Neuropathologica.

[9]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[10]  T. Meitinger,et al.  Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation , 2006, Annals of neurology.

[11]  B. Ghetti,et al.  Neurodegeneration Caused by Proteins with an Aberrant Carboxyl‐Terminus , 2004, Journal of neuropathology and experimental neurology.

[12]  Raffaele Lodi,et al.  Mitochondrial Dysfunction in Friedreich’s Ataxia , 2001, Neurosignals.

[13]  A. Filla,et al.  Magnetic resonance imaging in “typical” and “late onset” Friedreich's disease and early onset cerebellar ataxia with retained tendon reflexes , 1995, The Italian Journal of Neurological Sciences.

[14]  Mark A. Smith,et al.  In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease , 2000, Journal of neurochemistry.

[15]  P. Fox,et al.  Role of ceruloplasmin in cellular iron uptake. , 1998, Science.

[16]  C. Marsden,et al.  Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .

[17]  J. Poderoso,et al.  Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. , 2004, Molecular aspects of medicine.

[18]  M. Koenig,et al.  Friedreich ataxia: the oxidative stress paradox. , 2005, Human molecular genetics.

[19]  D. Ben-shachar,et al.  The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.

[20]  A Dürr,et al.  Clinical and genetic abnormalities in patients with Friedreich's ataxia. , 1996, The New England journal of medicine.

[21]  M. Emond,et al.  Increased levels of plasma malondialdehyde in Friedreich ataxia. , 2000, Neurology.

[22]  Y. Ke,et al.  Rethinking the role of ceruloplasmin in brain iron metabolism , 2001, Brain Research Reviews.

[23]  A. Rajput,et al.  Progressive Supranuclear Palsy , 2001, Drugs & aging.

[24]  S. Hayflick Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase–associated neurodegeneration is the name . . . , 2003, Current opinion in pediatrics.

[25]  G. Sawle,et al.  Palatal tremor and cognitive decline in neuroferritinopathy , 2002, Journal of neurology, neurosurgery, and psychiatry.

[26]  S Cluskey,et al.  Mechanisms of neurodegeneration in amyotrophic lateral sclerosis , 2001, Molecular pathology : MP.

[27]  Takashi Uehara,et al.  Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Lipton,et al.  Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function" , 2005, Science.

[29]  S. Mandel,et al.  Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.

[30]  J. Cooper,et al.  Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. , 2000, Human molecular genetics.

[31]  B. Carroll,et al.  Serum Melanotransferrin, p97 as a Biochemical Marker of Alzheimer's Disease , 2001, Neuropsychopharmacology.

[32]  P Trouillas,et al.  Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. , 1997, Human molecular genetics.

[33]  Katsuhide Ito,et al.  Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases , 1995, Journal of the Neurological Sciences.

[34]  J. Connor,et al.  Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences , 2004, Journal of the Neurological Sciences.

[35]  E. Gilbert-Barness,et al.  Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. , 1990, Pediatric Neurology.

[36]  W. Klein,et al.  Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein , 1995, Journal of neurochemistry.

[37]  M. Gurney,et al.  Disease mechanisms revealed by transcription profiling in SOD1‐G93A transgenic mouse spinal cord , 2001, Annals of neurology.

[38]  P. Riederer,et al.  In Vitro Studies of Ferritin Iron Release and Neurotoxicity , 1998, Journal of neurochemistry.

[39]  T. Dawson,et al.  Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function" , 2005, Science.

[40]  P. Riederer,et al.  Iron in brain function and dysfunction with emphasis on Parkinson's disease. , 1991, European neurology.

[41]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[42]  T. Montine,et al.  Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[43]  H. Miyajima,et al.  Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration , 1987, Neurology.

[44]  B. Liu,et al.  Role of Nitric Oxide in Inflammation‐Mediated Neurodegeneration , 2002, Annals of the New York Academy of Sciences.

[45]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[46]  W. D. Ehmann,et al.  Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study , 1995, Journal of the Neurological Sciences.

[47]  D. Dressler,et al.  Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy , 2004, Neurology.

[48]  Xudong Huang,et al.  An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.

[49]  T. Rouault,et al.  Iron on the brain , 2001, Nature Genetics.

[50]  W. Longstreth,et al.  Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes , 2003, Neurology.

[51]  F. Squitieri,et al.  Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. , 1993, Human molecular genetics.

[52]  M. Naoi,et al.  Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. , 2000, Toxicology.

[53]  T. Meitinger,et al.  An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. , 2003, Human molecular genetics.

[54]  M. Yorubulut,et al.  T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. , 2004, Neurology India.

[55]  Theodore W Randolph,et al.  Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. , 2003, Biochemistry.

[56]  P Z Marmarelis,et al.  MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.

[57]  P. Blumbergs,et al.  Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.

[58]  S. Mandel,et al.  Multifunctional Activities of Green Tea Catechins in Neuroprotection , 2005, Neurosignals.

[59]  W. D. Ehmann,et al.  Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress , 1996, Journal of the Neurological Sciences.

[60]  M. Mattson,et al.  Role of dietary iron restriction in a mouse model of Parkinson's disease , 2004, Experimental Neurology.

[61]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[62]  J. Cooper,et al.  Role of Oxidative Damage in Friedreich's Ataxia , 2004, Neurochemical Research.

[63]  A. L. Watson,et al.  In vitro polymerization of oxidized tau into filaments , 1993, Brain Research.

[64]  M. Frasier,et al.  Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.

[65]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[66]  R. Lill,et al.  Biogenesis of iron-sulfur proteins in eukaryotes: a novel task of mitochondria that is inherited from bacteria. , 2000, Biochimica et biophysica acta.

[67]  J. Kutok,et al.  The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. , 2006, Human molecular genetics.

[68]  H. Feldman,et al.  Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.

[69]  H. Miyajima,et al.  Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation , 2001, Neurology.

[70]  M. Frasier,et al.  Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.

[71]  Magnetic resonance relaxometry in Parkinson's disease , 2002, Neurological Sciences.

[72]  M. Ozeki,et al.  A case of clinically and neuropathologically atypical corticobasal degeneration with widespread iron deposition , 2002, Acta Neuropathologica.

[73]  Stephen A. Smith,et al.  Sea‐blue histiocytes, lymphocytic cytosomes, movement disorder and 59Fe‐uptake in basal ganglia , 1983, Neurology.

[74]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[75]  M. Savoiardo Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging , 2003, Neurological Sciences.

[76]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[77]  M. Naoi,et al.  Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines , 2002, Journal of Neural Transmission.

[78]  P. Harrison,et al.  The ferritins: molecular properties, iron storage function and cellular regulation. , 1996, Biochimica et biophysica acta.

[79]  F. Foury Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain , 1999, FEBS letters.

[80]  A. Coulthard,et al.  Neuroferritinopathy in a French family with late onset dominant dystonia , 2003, Journal of medical genetics.

[81]  A. Koeppen,et al.  Iron in the Hallervorden-Spatz syndrome. , 2001, Pediatric neurology.

[82]  E. Stadtman,et al.  Protein Oxidation in Aging and Age‐Related Diseases , 2001, Annals of the New York Academy of Sciences.

[83]  T. Fujiwara,et al.  Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia , 1998, Journal of Human Genetics.

[84]  M. Youdim,et al.  Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 , 2004, Annals of the New York Academy of Sciences.

[85]  J. Gitlin,et al.  Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. , 1998, The American journal of clinical nutrition.

[86]  M. Smith,et al.  Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? , 1999, Free radical biology & medicine.

[87]  Mark Hallett,et al.  Increased iron in the dentate nucleus of patients with Friedreich's ataxia , 1999, Annals of neurology.

[88]  J. Connor,et al.  Iron regulation in the brain: Histochemical, biochemical, and molecular considerations , 1992, Annals of neurology.

[89]  V. Seshadri,et al.  Ceruloplasmin Ferroxidase Activity Stimulates Cellular Iron Uptake by a Trivalent Cation-specific Transport Mechanism* , 1999, The Journal of Biological Chemistry.

[90]  M. Zigmond,et al.  Supersensitivity after intraventricular 6-hydroxydopamine: Relation to dopamine depletion , 1980, Experientia.

[91]  G. Perry,et al.  Oxidative Stress and Redox‐Active Iron in Alzheimer's Disease , 2004, Annals of the New York Academy of Sciences.

[92]  G. Rotilio,et al.  Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals , 2003, Brain Research Bulletin.

[93]  Y. Agid,et al.  Association study between iron-related genes polymorphisms and Parkinson's disease , 2002, Journal of Neurology.

[94]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[95]  T. Montine,et al.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. , 2004, Chemistry and physics of lipids.

[96]  R. Lill,et al.  An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1 , 2003, EMBO reports.

[97]  Gary Fiskum,et al.  Generation of reactive oxygen species by the mitochondrial electron transport chain , 2002, Journal of neurochemistry.

[98]  J. Cooper,et al.  Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.

[99]  J. Parisi,et al.  Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure , 1998, Annals of neurology.

[100]  G. Bartzokis,et al.  Increased basal ganglia iron levels in Huntington disease. , 1999, Archives of neurology.

[101]  M. MacDonald,et al.  Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. , 2000, Human molecular genetics.

[102]  L. Marnett,et al.  Oxyradicals and DNA damage. , 2000, Carcinogenesis.

[103]  R. Garruto,et al.  Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. , 1993, Neurotoxicology.

[104]  J. Delgado-García,et al.  Brain Damage and Repair , 2004, Springer Netherlands.

[105]  D. Berg,et al.  In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage , 2006, Journal of Neural Transmission.

[106]  Bertram Müller-Myhsok,et al.  Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease , 2005, Neuroscience Letters.

[107]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[108]  Mark A. Smith,et al.  4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.

[109]  K. Swaiman Hallervorden-Spatz syndrome. , 1990, Pediatric neurology.

[110]  M. Youdim,et al.  Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.

[111]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[112]  H. Miyajima,et al.  Aceruloplasminemia with a novel mutation associated with parkinsonism , 2000, Neurogenetics.

[113]  M. Youdim,et al.  Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. , 2005, Bioorganic & medicinal chemistry.

[114]  J. Bart,et al.  Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.

[115]  J. Valpuesta,et al.  Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. , 1998, The American journal of pathology.

[116]  A. Friedman,et al.  Controversies about iron in parkinsonian and control substantia nigra. , 1997, Acta neurobiologiae experimentalis.

[117]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[118]  M. Gerlach,et al.  Formation of Radicals , 2004 .

[119]  P. Kidd,et al.  Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. , 2000, Alternative medicine review : a journal of clinical therapeutic.

[120]  Elizabeth C. Theil Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. , 1987, Annual review of biochemistry.

[121]  J. Salamone,et al.  Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions , 1990, Neuroscience.

[122]  M. Youdim,et al.  Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition , 2005, Journal of neurochemistry.

[123]  K. Tipton,et al.  Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. , 1998, European Journal of Pharmacology.

[124]  K. Ohtomo,et al.  Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. , 1993, Radiology.

[125]  P. Hof,et al.  The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis , 1994, Brain Research.

[126]  M. Youdim,et al.  The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. , 1997, Pharmacology & toxicology.

[127]  M. Pandolfo,et al.  Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. , 1997, Science.

[128]  J. Connor,et al.  Abnormal localization of iron regulatory protein in Alzheimer's disease , 1998, Brain Research.

[129]  K. Marder,et al.  Dietary iron, animal fats, and risk of Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[130]  S. Murayama,et al.  Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.

[131]  J. Gitlin,et al.  Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[132]  B. Lemieux,et al.  The Cardiomyopathy of Friedreich's Ataxia Morphological Observations in 3 Cases , 1980, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[133]  H. Miyajima,et al.  Molecular and pathological basis of aceruloplasminemia. , 2006, Biological research.

[134]  W. Neupert,et al.  The mitochondrial proteins Ssq1 and Jac1 are required for the assembly of iron sulfur clusters in mitochondria. , 2001, Journal of molecular biology.

[135]  H. Reichmann,et al.  Mitochondrial dysfunction – a pathogenetic factor in Parkinson’s disease , 2000, Journal of Neurology.

[136]  S. Mandel,et al.  The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators , 1999, Annals of the New York Academy of Sciences.

[137]  Mark A. Wilson,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein , 2006 .

[138]  O. Hardiman,et al.  Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS , 2005, Neurology.

[139]  J. Sarsero,et al.  Friedreich's Ataxia, No Changes in Mitochondrial Labile Iron in Human Lymphoblasts and Fibroblasts , 2005, Journal of Biological Chemistry.

[140]  G Becker,et al.  Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography , 1995, Neurology.

[141]  C. Morris,et al.  Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.

[142]  H. Miyajima,et al.  Aceruloplasminemia, an inherited disorder of iron metabolism , 2003, Biometals.

[143]  G. Petsko,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. , 2006, Journal of molecular biology.

[144]  Makoto Hashimoto,et al.  Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease , 1998, Brain Research.

[145]  O. Rascol,et al.  Hereditary ferritinopathy , 2003, Journal of the Neurological Sciences.

[146]  R. Brooks,et al.  T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.

[147]  G. Arendash,et al.  Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex , 1995, Neuroscience.

[148]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[149]  Allan I. Levey,et al.  Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases* , 2004, Journal of Biological Chemistry.

[150]  D. Dickson,et al.  Multiple System Atrophy: A Sporadic Synucleinopathy , 1999, Brain pathology.

[151]  D. Butterfield,et al.  Free radicals and brain aging. , 2004, Clinics in geriatric medicine.

[152]  R. Krüger,et al.  The FASEB Journal express article 10.1096/fj.04-3486fje. Published online September 8, 2005. Functional relevance of ceruloplasmin mutations in Parkinson’s Disease , 2022 .

[153]  T. Taylor,et al.  Homozygosity mapping of Hallervorden–Spatz syndrome to chromosome 20p12.3–p13 , 1996, Nature Genetics.

[154]  A. Hutchinson,et al.  Mutation of a Putative Mitochondrial Iron Transporter Gene (ABC7) in X-Linked Sideroblastic Anemia and Ataxia (XLSA/A) , 1999, Human molecular genetics.

[155]  R. Lill,et al.  Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p , 1998, FEBS letters.

[156]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[157]  E. Hatchwell,et al.  X-linked sideroblastic anaemia with ataxia: another mitochondrial disease? , 2001, Journal of neurology, neurosurgery, and psychiatry.

[158]  S. Mandel,et al.  Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.

[159]  G. Bartzokis,et al.  In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. , 2000, Archives of general psychiatry.

[160]  E. Stopa,et al.  Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease , 1998, Experimental Neurology.

[161]  H. Shibasaki,et al.  Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. , 2001, Human molecular genetics.

[162]  N P Quinn,et al.  Clinicopathological study of 35 cases of multiple system atrophy. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[163]  J. Gitlin,et al.  Biochemical Analysis of a Missense Mutation in Aceruloplasminemia* , 2002, The Journal of Biological Chemistry.

[164]  Alberto Gatti,et al.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[165]  S. Gallati,et al.  Neuroferritinopathy: Missense mutation in FTL causing early-onset bilateral pallidal involvement , 2005, Neurology.

[166]  S. Aust,et al.  Stimulation of the ferroxidase activity of ceruloplasmin during iron loading into ferritin. , 1997, Archives of biochemistry and biophysics.

[167]  H U Rehman,et al.  Multiple system atrophy , 2001, Postgraduate medical journal.

[168]  E. Dooling,et al.  Hallervorden-Spatz syndrome. , 1974, Archives of neurology.

[169]  P. Ponka Hereditary Causes of Disturbed Iron Homeostasis in the Central Nervous System , 2004, Annals of the New York Academy of Sciences.

[170]  K F Swaiman,et al.  Hallervorden-Spatz syndrome and brain iron metabolism. , 1991, Archives of neurology.

[171]  J. Trojanowski,et al.  Altered Neuronal Mitochondrial Coenzyme A Synthesis in Neurodegeneration with Brain Iron Accumulation Caused by Abnormal Processing, Stability, and Catalytic Activity of Mutant Pantothenate Kinase 2 , 2005, The Journal of Neuroscience.

[172]  James R. Connor,et al.  Brain iron uptake and homeostatic mechanisms: An overview , 2003, Biometals.

[173]  R. Lill,et al.  The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins , 1999, The EMBO journal.

[174]  T. Bird,et al.  Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. , 1985, Journal of medical genetics.

[175]  W. D. Ehmann,et al.  Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. , 1998, Neurotoxicology.

[176]  C. C. Johnson,et al.  Adult nutrient intake as a risk factor for Parkinson's disease. , 1999, International journal of epidemiology.

[177]  W. Halliday,et al.  Hallervorden-Spatz disease: MR and pathologic findings. , 1993, AJNR. American journal of neuroradiology.

[178]  T. Hirokawa,et al.  Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.

[179]  M. Youdim,et al.  Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. , 1995, European journal of pharmacology.

[180]  Ashley I. Bush,et al.  Redox-active iron mediates amyloid-β toxicity , 2001 .

[181]  C. Crosio,et al.  Superoxide dismutase 1 modulates expression of transferrin receptor , 2006, JBIC Journal of Biological Inorganic Chemistry.

[182]  J. Tolmie,et al.  Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. , 2000, Blood.

[183]  R I Grossman,et al.  Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes , 1989, Neurology.

[184]  C. Quintana,et al.  Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. , 2006, Journal of structural biology.

[185]  P. Arosio,et al.  Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. , 2005, Best practice & research. Clinical haematology.

[186]  J. Sung,et al.  PATHOLOGY OF SHY‐DRAGER SYNDROME* , 1978, Journal of neuropathology and experimental neurology.

[187]  Shawn K. Westaway,et al.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.

[188]  P. Bauer,et al.  Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease , 2004, Neurology.

[189]  J. Witztum,et al.  Abnormal Iron Deposition Associated With Lipid Peroxidation in Transgenic Mice Expressing lnterleukin-6 in the Brain , 1998, Journal of neuropathology and experimental neurology.

[190]  C. Batich,et al.  In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. , 2005, Journal of Alzheimer's disease : JAD.

[191]  S. Mandel,et al.  cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[192]  Rabi Tawil,et al.  Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. , 2005, Journal of neuropathology and experimental neurology.

[193]  J. Gitlin,et al.  Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. , 1996, Human molecular genetics.

[194]  Sun-Young Lee,et al.  Lipid interaction of α‐synuclein during the metal‐catalyzed oxidation in the presence of Cu2+ and H2O2 , 2003, Journal of neurochemistry.

[195]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[196]  R. Benecke,et al.  Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease , 2002, Journal of Neural Transmission.

[197]  M. Youdim,et al.  Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion , 2005, Journal of neurochemistry.

[198]  Ya Ke,et al.  Iron misregulation in the brain: a primary cause of neurodegenerative disorders , 2003, The Lancet Neurology.

[199]  T. Montine,et al.  Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans , 2002, Neuroscience Letters.

[200]  C. Glabe,et al.  Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's A beta peptide studied by fluorescence. , 1999, Bioorganic & medicinal chemistry letters.

[201]  Sri Nabawiyati nurul Makiyah Cell Signaling Pathways in the Neuroprotective Actions of the Green Tea Polyphenol (-)-epigallocatechin-3-gallate: Implications for Neurodegenerative Diseases , 2005 .

[202]  D. Praticò In vivo measurement of the redox state , 2001, Lipids.

[203]  M. Smith,et al.  Redox-active iron mediates amyloid-beta toxicity. , 2001, Free radical biology & medicine.

[204]  C. Marsden,et al.  Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.

[205]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[206]  Y. Wada,et al.  Hereditary ceruloplasmin deficiency with hemosiderosis , 1996, Human Genetics.

[207]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[208]  G. Bartzokis,et al.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.

[209]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[210]  R M Henkelman,et al.  MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. , 1993, AJNR. American journal of neuroradiology.

[211]  O. Rascol,et al.  Intracellular Ferritin Accumulation in Neural and Extraneural Tissue Characterizes a Neurodegenerative Disease Associated with a Mutation in the Ferritin Light Polypeptide Gene , 2004, Journal of neuropathology and experimental neurology.

[212]  G. Brittenham,et al.  Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. , 1997, The American journal of physiology.

[213]  G. C. Ferreira,et al.  Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. , 2006, Human molecular genetics.

[214]  N P Quinn,et al.  Olivopontocerebellar pathology in multiple system atrophy , 1996, Movement disorders : official journal of the Movement Disorder Society.

[215]  A. Abeliovich,et al.  DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.

[216]  K. Tipton,et al.  Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine , 1996, Journal of neurochemistry.

[217]  G Becker,et al.  Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.

[218]  Ken-ichi Isobe,et al.  An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells , 2003, Journal of neuroscience research.

[219]  M. Prieto-Carrasquero,et al.  'In vivo diagnosis of Hallervorden-Spatz disease'. , 1996, Developmental medicine and child neurology.

[220]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[221]  D. Richardson,et al.  Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. , 2001, The international journal of biochemistry & cell biology.

[222]  R. Allikmets,et al.  Evolution of ATP-binding cassette transporter genes. , 1995, Current opinion in genetics & development.

[223]  M. Youdim,et al.  Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. , 2000, Cellular and molecular biology.

[224]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[225]  M. Vérin,et al.  Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. , 2002, Journal of hepatology.

[226]  S. Fahn,et al.  Study of movement disorders and brain iron by MR. , 1987, AJR. American journal of roentgenology.

[227]  E. Ciceri,et al.  Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. , 1994, Journal of neural transmission. Supplementum.

[228]  M Hutchinson,et al.  Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.

[229]  A. Nakamura,et al.  Increased lipid peroxidation in the brains of aceruloplasminemia patients , 2000, Journal of the Neurological Sciences.

[230]  C. Rock,et al.  Cloning and Characterization of a Eukaryotic Pantothenate Kinase Gene (panK) from Aspergillus nidulans * , 1999, The Journal of Biological Chemistry.

[231]  T. Siddique,et al.  Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[232]  Daniela Berg,et al.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.

[233]  P. Mantyh,et al.  Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.

[234]  Irene Litvan,et al.  Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia , 2003, Annals of neurology.

[235]  F. Ye,et al.  Increased Basal Ganglia Iron in Striatonigral Degeneration: In Vivo Estimation with Magnetic Resonance , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[236]  D. Radisky,et al.  The Yeast Frataxin Homologue Mediates Mitochondrial Iron Efflux , 1999, The Journal of Biological Chemistry.

[237]  A. Munnich,et al.  Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia , 1997, Nature Genetics.

[238]  Robert B. Wilson,et al.  Increased IRP1 activity in Friedreich ataxia. , 2005, Gene.

[239]  W. Jefferies,et al.  Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin , 1996, Brain Research.

[240]  G M SHY,et al.  A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. , 1960, Archives of neurology.

[241]  D. Loeffler,et al.  Ceruloplasmin immunoreactivity in neurodegenerative disorders , 2001, Free radical research.

[242]  P. Lantos,et al.  Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.

[243]  J. Connor,et al.  Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.

[244]  P. Blumbergs,et al.  Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.

[245]  J. Jankovic,et al.  Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden‐Spatz syndrome) and pantothenate kinase‐associated neurodegeneration , 2004, Movement disorders : official journal of the Movement Disorder Society.